Ireland - English - HPRA (Health Products Regulatory Authority)

bracco international b.v. - gadoteridol - solution for injection - 279.3 milligram(s)/millilitre - paramagnetic contrast media; gadoteridol

Ireland - English - HPRA (Health Products Regulatory Authority)

bracco international b.v. - gadoteridol - solution for injection - 279.3 milligram(s)/millilitre - paramagnetic contrast media; gadoteridol

Ireland - English - HPRA (Health Products Regulatory Authority)

bracco international b.v. - gadoteridol - solution for injection - 279.3 milligram(s)/millilitre - paramagnetic contrast media; gadoteridol

European Union - English - EMA (European Medicines Agency)

bracco international b.v. - sulphur hexafluoride - ultrasonography; echocardiography - contrast media - this medicinal product is for diagnostic use only.sonovue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.sonovue should only be used in patients where study without contrast enhancement is inconclusive.echocardiographysonovue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.doppler of macrovasculaturesonovue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the doppler signal to noise ratio.sonovue increases the quality of the doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.doppler of microvasculaturesonovue improves display of the vascularity of liver and breast lesions during doppler sonography in adult patients leading to more specific lesion characterisation.ultrasonography of excretory urinary tractsonovue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. for the limitation in the interpretation of a negative urosonography.

Ireland - English - HPRA (Health Products Regulatory Authority)

bracco international b.v. - gadoteridol - solution for injection - 279.3 mg/m mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; calteridol calcium; trometamol; sodium hydroxide; water for injections - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine -

Australia - English - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - iomeprol -